Title
“Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma
Code
PM1183-C-010-22
Type
Sperimentale con farmaco
Start Year
2024
Status
In Corso
Principal Investigator
051-6366102
toni.ibrahim@ior.it
Director
Operational unit that carry out the study
complex unit
Osteoncologia, Sarcomi dell'osso e dei tessuti molli, e Terapie Innovative
Director
:Documents and Videos attachament
Attachment
PG0004314_2024_Stampa_unica.pdf